Alembic Pharmaceuticals reported a significant rise in its consolidated net profit, which increased by 29.19% to ₹202.70 crore for the fourth quarter of FY26, compared to ₹156.89 crore in the same period last year. Revenue from operations also saw a 4.41% year-on-year growth, reaching ₹1,847.72 crore. The profit before tax (PBT) rose by 38.20% to ₹118.62 crore. The company's India Branded Business contributed ₹568 crore, reflecting a 4% increase, supported by strong performance in key therapeutic areas such as gynaecology and gastroenterology. The international segment performed well, with US formulations growing 11% to ₹564 crore, bolstered by six new product launches. Alembic also entered the US branded pharmaceuticals market with the launch of Pivya, a first-line oral antibiotic for uncomplicated urinary tract infections in women. Managing Director Pranav Amin highlighted the disciplined execution and focus on profitability during this quarter. The company has also proposed a ₹12 dividend per equity share, marking a 600% return for shareholders for the fiscal year.